News - EPHA3 mutation

2ms

Clinicopathological characteristics and genetic features of young and senior Ewing sarcoma patients. (PubMed, Diagn Pathol)

Clinicopathological characteristics and genetic features in young and senior EwS patients differed significantly. Targeting cell cycle dysregulation based on age subgroup may be a potential therapeutic strategy for Ewing sarcoma.

2 months ago

Journal

CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • EWSR1 (EWS RNA Binding Protein 1) • STAG2 (Stromal Antigen 2) • ERG (ETS Transcription Factor ERG) • CHEK1 (Checkpoint kinase 1) • EPHA3 (EPH receptor A3) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • SLIT2 (Slit Guidance Ligand 2)

CCND1 amplification • CDK4 amplification • STAG2 mutation • CCND1 expression • EWSR1-FLI1 fusion • CCND1-H • EPHA3 mutation • CHEK1 expression

9ms

Genetic alterations predict poor efficacy, outcomes and resistance to second-line osimertinib treatment in non-small cell lung cancer. (PubMed, Am J Cancer Res)

Additionally, HIST1H2BD represents a novel resistance mutation to osimertinib. All of these findings offer valuable insights for making personalized treatment strategies for NSCLC patients.

9 months ago

Journal

HGF (Hepatocyte growth factor) • RBM10 (RNA Binding Motif Protein 10) • RAC1 (Rac Family Small GTPase 1) • EPHA3 (EPH receptor A3) • GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • H2BC8 (H2B Clustered Histone 8) • PAK1 (p21 (RAC1) activated kinase 1) • PAK5 (P21 (RAC1) Activated Kinase 5)

EPHA3 mutation • RBM10 mutation

Tagrisso (osimertinib)

10ms

Contrasting Effects of Cancer-Associated Mutations in EphA3 and EphB2 Kinases. (PubMed, Biochemistry)

The reciprocal effects of EphB2 and EphA3 on ERK phosphorylation in HEK293T cells were also evident in Ras-GTP loading. Thus, consistent with the dual roles of Eph receptors as tumor promoters and tumor suppressors, somatic mutations have the potential to increase or decrease Eph function, resulting in changes in the downstream signaling transduction.

10 months ago

Journal

EPHA3 (EPH receptor A3) • EPHB2 (EPH Receptor B2)

EPHA3 mutation

1year

A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient. (PubMed, Cell Death Discov)

Altogether, these findings support an unveiled link between BRCA2 inactivation, HR deficiency and increased expression of immune checkpoints in TNBC. This clinical case highlights the importance of screening TNBC patients for genetic mutations and TMB biomarkers in order to predict the potential efficacy of immunotherapy.

1 year ago

Journal • Tumor mutational burden • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • PD-1 (Programmed cell death 1) • BAP1 (BRCA1 Associated Protein 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • EPHA3 (EPH receptor A3)

TP53 mutation • BRCA2 mutation • BRCA1 mutation • TMB-H • HRD • BAP1 mutation • HRD + BRCA1 mutation • EPHA3 mutation • HRD signature

almost2years

Progressive abdominal pain with acute exacerbation due to retroperitoneal follicular dendritic cell sarcoma: a case report with targeted genomic sequencing analysis. (PubMed, Acta Chir Belg)

The interpretations of CA724, PET/CT, as well as imaging results deserve further investigation in FDCS. Genomic sequencing revealed three novel gene mutations in FDCS, including EPHA3 (nonsense mutation), DDR2 (SNV), and BIRC3 (InDel).

almost 2 years ago

Journal

BIRC3 (Baculoviral IAP repeat containing 3) • EPHA3 (EPH receptor A3) • DDR2 (Discoidin domain receptor 2)

EPHA3 mutation

over3years

[VIRTUAL] The predictive values of EPHA3 mutations for response to immune checkpoint inhibitors in solid tumors (ESMO 2021)

Our data indicated that EPHA3 mutations were associated with prolonged OS in NSCLC, rather than other cancer types, suggesting that it might act as a predictive biomarker for ICIs therapy in NSCLC. EPHA3 mutations were also correlated with higher TMB and increased activated natural killer cells in NSCLC.

over 3 years ago

Checkpoint inhibition • Tumor Mutational Burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • EPHA3 (EPH receptor A3) • EPHA5 (EPH Receptor A5) • EPHA7 (EPH Receptor A7)

PD-L1 expression • TMB-H • MSI-H/dMMR • EPHA3 mutation • EPHA7 mutation